Zardaverine
Zardaverine is an orally active and selective PDE3/4 inhibitor (IC50) =0.58 uM/0.17 uM) with potent bronchodilator activity. Zardaverine also selectively inhibits the proliferation of HCC cells and induces apoptosis and cycle arrest (G0/G1 phase) . Zardaverine has good antitumor potential and is effective in both bronchial relaxation and reduction of inflammation in asthma[1][2][3].
Product Specifications
CAS Number
101975-10-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Zardaverine.html
Concentration
10mM
Purity
98.64
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C1C=CC(C2=CC=C(OC(F)F)C(OC)=C2)=NN1
Molecular Formula
C12H10F2N2O3
Molecular Weight
268.22
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDE3; PDE4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD44 Standard (DF1485), CF640R conjugate, 0.1mg/mL
CD45RO (190-2F2.5), CF594 conjugate, 0.1mg/mL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF740 conjugate, 0.1mg/mL
CD45RO (190-2F2.5), CF647 conjugate, 0.1mg/mL
